在新西兰进行临床试验,测试口服药物,以预防生殖器性疹的复发性。 Clinical trial in New Zealand to test oral medication for recurrent genital herpes prevention.

新西兰的临床试验将测试一种新的药品,以防止生殖器性疹复发,这影响到80%的人口。 A clinical trial in New Zealand will test a new medication aimed at preventing recurrences of genital herpes, which affects 80% of the population. 该试验针对18至60岁的复发性疹患者, 试图确定药物是否能阻止HSV-2的重新激活. Targeting individuals aged 18-60 with recurrent herpes, the trial seeks to determine if the medication can stop HSV-2 from reactivating. 如果成功,口服药物可以每周或较少时间服用,提供新的治疗选择。 If successful, the oral medication could be taken weekly or less often, providing a new treatment option. 参加者可因其参与而获得赔偿。 Participants may receive compensation for their involvement.